- BioStem Technologies (OTC: BSEM) engages with CMS on proposed reimbursement changes for skin substitutes.
- Conducting randomized controlled trials for BioREtain® technology with results expected in 2025.
- Progressing with Form 10 filing; plans Nasdaq uplisting update during Q2 2025 earnings call.
BioStem Technologies, Inc. (OTC: BSEM), a MedTech company known for its innovative placental-derived wound care products, has announced its support for the proposed changes by the Centers for Medicare and Medicaid Services (CMS) regarding reimbursement methodologies for skin substitutes as part of the Calendar Year (CY) 2026 Physician Fee Schedule (PFS) and Outpatient Prospective Payment System (OPPS). CEO Jason Matuszewski affirmed the company's commitment to working with CMS and other stakeholders during the designated 60-day comment period to refine its approach.
As part of its ongoing innovation efforts, BioStem is conducting randomized controlled trials (RCTs) to evaluate its BioREtain® technology across various medical indications. The company anticipates releasing initial trial results later in 2025, which could potentially cement BioREtain®'s clinical superiority as a crucial element of their commercial products.
Simultaneously, BioStem is advancing its Form 10 filing process, which is crucial for its planned uplisting to Nasdaq. The company intends to provide further updates regarding its Nasdaq listing progress during its second-quarter earnings call in 2025.
BioStem remains committed to leveraging its proprietary BioREtain® processing method to enhance regenerative therapies. By focusing on maintaining growth factors and preserving tissue structure, BioStem continues to drive significant advancements in advanced wound care solutions.
